Carcinogenesis, Vol. 23, No. 3, 425-432,
March 2002
© 2002 Oxford University Press
MOLECULAR EPIDEMIOLOGY |
Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53
Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA
Abstract
Dietary phenolic substances including resveratrol, a stillbene compound, are found in several fruits and vegetables, and these compounds have been reported to have anti-oxidant, anti-inflammatory and antitumorigenic activities. However, the molecular mechanisms underlying the antitumorigenic or chemopreventive activities of these compounds remain largely unknown. The expression of NAG-1 [non-steroidal anti-inflammatory (NSAID) drug-activated gene-1], a member of the transforming growth factor-beta (TGF-ß) superfamily, has been shown to be associated with pro-apoptotic and antitumorigenic activities. Here, we have demonstrated that resveratrol induces NAG-1 expression and apoptosis in a concentration-dependent manner. Resveratrol increases the expression of p53, tumor suppressor protein, prior to NAG-1 induction, indicating that NAG-1 expression by resveratrol is mediated by p53 expression. We also show that the p53 binding sites within the promoter region of NAG-1 play a pivotal role to control NAG-1 expression by resveratrol. Derivatives of resveratrol were examined for NAG-1 induction, and the data suggest that resveratrol-induced NAG-1 and p53 induction is not dependent on its anti-oxidant activity. The data may provide linkage between p53, NAG-1 and resveratrol, and in part, a new clue to the molecular mechanism of the antitumorigenic activity of natural polyphenolic compounds.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Shim and T. E. Eling Vitamin E succinate induces NAG-1 expression in a p38 kinase-dependent mechanism Mol. Cancer Ther., April 1, 2008; 7(4): 961 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhou, Y. Zhong, Y. Wang, X. Zhang, D. L. Batista, R. Gejman, P. J. Ansell, J. Zhao, C. Weng, and A. Klibanski Activation of p53 by MEG3 Non-coding RNA J. Biol. Chem., August 24, 2007; 282(34): 24731 - 24742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Selander, D. A. Brown, G. B. Sequeiros, M. Hunter, R. Desmond, T. Parpala, J. Risteli, S. N. Breit, and A. Jukkola-Vuorinen Serum Macrophage Inhibitory Cytokine-1 Concentrations Correlate with the Presence of Prostate Cancer Bone Metastases Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 532 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Soto-Cerrato, F. Vinals, J. R. Lambert, J. A. Kelly, and R. Perez-Tomas Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3{beta} activity in human breast cancer cells Mol. Cancer Ther., January 1, 2007; 6(1): 362 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Martinez, T. Sali, R. Okazaki, C. Anna, M. Hollingshead, C. Hose, A. Monks, N. J. Walker, S. J. Baek, and T. E. Eling Drug-Induced Expression of Nonsteroidal Anti-Inflammatory Drug-Activated Gene/Macrophage Inhibitory Cytokine-1/Prostate-Derived Factor, a Putative Tumor Suppressor, Inhibits Tumor Growth J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 899 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-H. Lee, K. Yamaguchi, J.-S. Kim, T. E. Eling, S. Safe, Y. Park, and S. J. Baek Conjugated linoleic acid stimulates an anti-tumorigenic protein NAG-1 in an isomer specific manner Carcinogenesis, May 1, 2006; 27(5): 972 - 981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yamaguchi, S.-H. Lee, T. E. Eling, and S. J. Baek A novel peroxisome proliferator-activated receptor {gamma} ligand, MCC-555, induces apoptosis via posttranscriptional regulation of NAG-1 in colorectal cancer cells Mol. Cancer Ther., May 1, 2006; 5(5): 1352 - 1361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chintharlapalli, S. Papineni, and S. Safe 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes inhibit colon cancer cell and tumor growth through PPAR{gamma}-dependent and PPAR{gamma}-independent pathways Mol. Cancer Ther., May 1, 2006; 5(5): 1362 - 1370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Boyer, W. L. Allen, E. G. McLean, P. M. Wilson, A. McCulla, S. Moore, D. B. Longley, C. Caldas, and P. G. Johnston Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res., March 1, 2006; 66(5): 2765 - 2777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chintharlapalli, S. Papineni, S. J. Baek, S. Liu, and S. Safe 1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes Are Peroxisome Proliferator-Activated Receptor {gamma} Agonists but Decrease HCT-116 Colon Cancer Cell Survival through Receptor-Independent Activation of Early Growth Response-1 and Nonsteroidal Anti-Inflammatory Drug-Activated Gene-1 Mol. Pharmacol., December 1, 2005; 68(6): 1782 - 1792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Kim, S. J. Baek, F. G. Bottone Jr., T. Sali, and T. E. Eling Overexpression of 15-Lipoxygenase-1 Induces Growth Arrest through Phosphorylation of p53 in Human Colorectal Cancer Cells Mol. Cancer Res., September 1, 2005; 3(9): 511 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shim and T. E. Eling Protein Kinase C-dependent Regulation of NAG-1/Placental Bone Morphogenic Protein/MIC-1 Expression in LNCaP Prostate Carcinoma Cells J. Biol. Chem., May 13, 2005; 280(19): 18636 - 18642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. G. Bottone Jr., Y. Moon, J. S. Kim, B. Alston-Mills, M. Ishibashi, and T. E. Eling The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3) Mol. Cancer Ther., May 1, 2005; 4(5): 693 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-S. Kim, S. J. Baek, T. Sali, and T. E. Eling The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15 Mol. Cancer Ther., March 1, 2005; 4(3): 487 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Baek, J.-S. Kim, S. M. Moore, S.-H. Lee, J. Martinez, and T. E. Eling Cyclooxygenase Inhibitors Induce the Expression of the Tumor Suppressor Gene EGR-1, Which Results in the Up-Regulation of NAG-1, an Antitumorigenic Protein Mol. Pharmacol., February 1, 2005; 67(2): 356 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Jain, S. M. Moore, K. Yamaguchi, T. E. Eling, and S. J. Baek Selective Nonsteroidal Anti-Inflammatory Drugs Induce Thymosin {beta}-4 and Alter Actin Cytoskeletal Organization in Human Colorectal Cancer Cells J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 885 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Baek, J.-S. Kim, F. R. Jackson, T. E. Eling, M. F. McEntee, and S.-H. Lee Epicatechin gallate-induced expression of NAG-1 is associated with growth inhibition and apoptosis in colon cancer cells Carcinogenesis, December 1, 2004; 25(12): 2425 - 2432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yamaguchi, S.-H. Lee, T. E. Eling, and S. J. Baek Identification of Nonsteroidal Anti-inflammatory Drug-activated Gene (NAG-1) as a Novel Downstream Target of Phosphatidylinositol 3-Kinase/AKT/GSK-3{beta} Pathway J. Biol. Chem., November 26, 2004; 279(48): 49617 - 49623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Baek, J.-S. Kim, J. B. Nixon, R. P. DiAugustine, and T. E. Eling Expression of NAG-1, a Transforming Growth Factor-{beta} Superfamily Member, by Troglitazone Requires the Early Growth Response Gene EGR-1 J. Biol. Chem., February 20, 2004; 279(8): 6883 - 6892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Newman, M. Sakaue, J. S. Koo, K.-S. Kim, S. J. Baek, T. Eling, and A. M. Jetten Differential Regulation of Nonsteroidal Anti-Inflammatory Drug-Activated Gene in Normal Human Tracheobronchial Epithelial and Lung Carcinoma Cells by Retinoids Mol. Pharmacol., March 1, 2003; 63(3): 557 - 564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Baek, L. C. Wilson, L. C. Hsi, and T. E. Eling Troglitazone, a Peroxisome Proliferator-activated Receptor gamma (PPARgamma ) Ligand, Selectively Induces the Early Growth Response-1 Gene Independently of PPARgamma . A NOVEL MECHANISM FOR ITS ANTI-TUMORIGENIC ACTIVITY J. Biol. Chem., February 14, 2003; 278(8): 5845 - 5853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Wong, P.-X. Li, and H. J. Klamut A Novel p53 Transcriptional Repressor Element (p53TRE) and the Asymmetrical Contribution of Two p53 Binding Sites Modulate the Response of the Placental Transforming Growth Factor-beta Promoter to p53 J. Biol. Chem., July 12, 2002; 277(29): 26699 - 26707. [Abstract] [Full Text] [PDF]
|
|